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Background: Trastuzumab is widely used as the treatment of choice for HER2-positive metastatic breast cancer
(MBC).
Patients and methods: Seventy patients, median age 57 years and range 31–81 years, were included in our
retrospective analysis with the aim to evaluate safety and activity of trastuzumab-containing therapies.
Results: We observed for first-line treatment response rate (RR) 41%, stable disease (SD) 47% and time to
progression (TTP) 8 months (range 1–44). Corresponding numbers for second line were RR 23%, SD 62% and (TTP) 9
months (range 3–23) and beyond second line RR 22%, SD 78% and (TTP) 9 months (range 4–19). Overall survival was
19.2 months (3–62 months). The median cumulative dose of trastuzumab administrated was 5286 mg
(464–17 940 mg). Trastuzumab was well tolerated. Median left ventricular ejection function (LVEF) at baseline was
62% and at the end of treatment was 59%. The more relevant adverse events consisted of an asymptomatic
decrease in LVEF to 40% (baseline 60%) and a grade 3 symptomatic increase in bilirubin.
Conclusion: Trastuzumab-containing therapies in MBC show a good safety and toxicity profile and a remarkable
activity even in heavily pretreated women. Patients should benefit from continued trastuzumab therapy, as shown
by the maintenance of (TTP) even beyond second-line treatment.
Key words: cardiac safety, clinical experience, heavily pretreated women, metastatic breast cancer, retrospective
analysis, trastuzumab
introduction
Breast cancer represents the main cause of cancer morbidity
and mortality in women in most countries all over the world
[1].
Metastatic breast cancer (MBC) remains an incurable
disease, but in the last decade the development of new
cytotoxic drugs and combinations and the introduction
of novel targeted agents have permitted to lengthen patient’s
survival and improve quality of life.
The clinical introduction of trastuzumab, a humanized
monoclonal antibody directed against the HER2/neu protein,
has drastically altered the lives of many women with
HER-2-overexpressing tumors. This anticancer agent plays
an important role in breast cancer treatment.
Overexpression of HER-2 and amplification of the HER-2
gene occur in 25%–30% of cases of MBC [2] and are usually
associated with a particularly aggressive clinical course and
consequently with a poor prognosis and shortened overall
survival (OS).
Preclinical models have shown a significant antitumor
activity of trastuzumab as a single agent [3] and additive or
even synergistic effects in combination with chemotherapy
drugs commonly used in the treatment of breast cancer,
especially taxanes, vinorelbine and platinum agents [4].
On the basis of these encouraging observations, multiple
clinical trials were designed in order to investigate safety and
clinical activity of trastuzumab in MBC, first as monotherapy
and subsequently in combination. The response rates achieved
as monotherapy were of 20%–25% as first-line therapy [5] and
10%–15% in patients [6, 7] pretreated with chemotherapy for
metastatic disease.
Two pivotal phase III trial compared first-line chemotherapy
alone with the combination of chemotherapy with trastuzumab
in patients with HER/2-positive MBC [8, 9]. The addition of
trastuzumab significantly improved all clinical endpoints [time
to progression (TTP), RR, duration of response and survival).
In these trials, there was an unexpected high frequency of
cardiotoxicity in patients treated with trastuzumab and
chemotherapy.
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A retrospective analysis showed that trastuzumab-associated
cardiac events mainly occurred with concomitant use of
anthracyclines (mainly doxorubicin) [10].
Consequently, this combination is not currently indicated for
clinical use. Several trials have investigated the cardiac safety
and efficacy of anthracyclines less cardiotoxic than
doxorubicin, such as epirubicin or liposomal formulations of
doxorubicin combined with trastuzumab [11, 12].
Both pivotal trials demonstrated a favorable safety profile for
trastuzumab plus taxanes [8, 9].
This safe and effective combination is recommended as
first-line chemotherapy for patients with HER-2-positive MBC.
In order to improve treatment efficacy and for the increasing
use of taxanes in the adjuvant setting, new combinations of
trastuzumab and chemotherapy drugs, such as vinorelbine,
gemcitabine and capecitabine, have been investigated with
encouraging results.
One of the most active non-taxane regimen is the
combination of trastuzumab with vinorelbine, with RR of
68%–78% as first-line chemotherapy and a good profile of
tolerability, also for the absence of alopecia [13].
Some associations of trastuzumab with chemotherapy
combinations have shown interesting data of safety and
efficacy. The addition of platinum salts to taxanes and
trastuzumab has significantly enhanced the efficacy of this
combination doublet [14,15,16].
The potential benefit in a responding patient with MBC to
continue trastuzumab with a new chemotherapy drug or in
monotherapy is a topic of great interest.
Unfortunately, most of the metastatic patients develop
disease progression during the treatment.
In these patients, to stop or continue trastuzumab is
controversy [17].
In the clinical practice, there is a consensus to continue
trastuzumab beyond progression supported by preclinical
observations and clinical data, but there are no mature data
from randomized trials [18].
Data collected from clinical trials show a good safety profile
of trastuzumab combinations and manageable toxic effects that
encourage its use in our clinical practice, but an attentive
observation is necessary to investigate long-term tolerability,
above all in heavily pretreated patients.
We report in this paper our long-term clinical experience
on safety and efficacy of trastuzumab as monotherapy or in
combination in MBC patients.
patients and methods
We have conducted a retrospective analysis and collected information on
70 women with histological confirmed HER2-positive MBC, who received
trastuzumab-based therapy between May 2001 and June 2006. Standard
trastuzumab infusion was administrated until disease progression or serious
adverse events.
Median age was 57 years and range 31–81 years. Most patients had good
performance status at entry (Eastern Cooperative Oncology Group 0 or 1).
Twenty-six patients had positive estrogen and progesterone receptors.
Median number of metastatic sites was 2 and range 1–6. Thirty patients had
only visceral metastases, 21 in bone or the soft tissue and the remaining
19 patients had metastases in more risk groups.
Most of the women (66%) had received prior chemotherapy in adjuvant
or neo-adjuvant setting, with 17 patients receiving anthracycline-based
regimens, 2 taxane-containing therapies and 13 both anthracycline- and
taxane-based regimens. Adjuvant endocrine therapy was administered in
27 patients.
Ten patients had metastatic disease at the time of primary diagnosis.
Twenty-five patients had received a median number of two previous lines of
chemotherapy for metastatic disease (range 1–5). Palliative endocrine
therapy was administered in 11 patients.
The characteristics of patients are summarized in Table 1.
statistical analysis
Disease responses were recorded according to the Response Evaluation
Criteria in Solid Tumors guidelines [19]. Toxicity was assessed according to
the National Cancer Institute Common Toxicity Criteria system [20] and
was recorded for the worst episode occurred.
Table 1. Patients characteristics
Characteristics No. of
patients (%)
Age (years)
Median 57
Range 31–81
ECOG performance status
0 56 (80)
1 12 (17)
2 2 (3)
Estrogen receptors
Positive 40 (57)
Negative 27 (39)
Unknown 3 (4)
Progesterone receptors
Positive 28 (40)
Negative 36 (51)
Unknown 6 (9)
Estrogen and progesterone receptors positive 26 (37)
No. of metastatic sites
1 29 (41)
2 32 (46)
>3 9 (13)
Metastatic sites median (range) 2 (1–6 sites)
Dominant site of disease
Bone 8 (11)
Visceral 30 (43)
Soft tissue 13 (19)
Bone and visceral 14 (20)
Bone, visceral and soft tissue 5 (7)
Adjuvant or neo-adjuvant chemotherapy 46 (66)
Prior exposure to anthracycline 17
Prior exposure to taxane 2
Prior exposure to both 13
Adjuvant endocrine therapy 27 (39)
Metastatic disease at the diagnosis 10 (14)
Prior therapy for metastatic disease
Chemotherapy 25 (36)
Endocrine therapy 11 (16)
ECOG, Eastern Cooperative Oncology Group.
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Baseline echocardiography data were recorded and the development of
left ventricular ejection function (LVEF) during treatment was reported.
(TTP) was defined as the interval from the first day of application of
a new therapy line until tumor progression.
OS was calculated from the day of the first administration of
trastuzumab-based therapy to the date of death. Patients alive were
censored at the date of the last follow-up contact.
We did not perform statistical comparison of the clinical outcomes in
different patient settings for the limited number of patients and the
descriptive aim of our retrospective analysis particularly focused on
long-term tolerability of trastuzumab-based therapy.
results
Trastuzumab was used first time as monotherapy in
12 patients and in combination in 58 patients.
The associations were with vinorelbine (n = 28), docetaxel
(n = 17) and paclitaxel (n = 13). Six patients (8%) had
a complete response (CR) and 23 (33%) a partial response
(PR); 33 (47%) patients showed stable disease (SD) and
8 (12%) had a progressive disease (PD).
Twenty-six patients received a second trastuzumab-
containing therapy, 14 as monotherapy and 12 in
combination (four patients with vinorelbine, three with
taxanes, two with pegylated liposomal doxorubicin and
three with gemcitabine).
Responses for second-line treatment were: 6 (23%) patients
had PR, 16 (62%) SD and 4 (15%) PD. Further lines of
trastuzumab-based regimen were administered in nine patients
with an overall response rate of 22%. A patient treated in third
line with the association of pegylated liposomal doxorubicin
obtained an interesting CR, after a SD in first line and a PR
in the second.
Among patients treated in third or fourth line, no PD was
recorded and seven patients obtained a good control of the
disease. The tumor responses in the different lines are shown in
Table 2.
(TTP) was 8 months (range 1–44) in the first-line setting, 9
months (range 3–23) in the second line and also 9 months
(range 4–19) beyond second line.
The median OS was 19.2 months with a range of 3–62
months.
Median cumulative dose of trastuzumab administered was
5286 mg (range 464–17 940).
Trastuzumab-based therapy was well tolerated also in
combination. Cardiotoxicity was manageable and we did not
observed signs or symptoms of congestive heart failure or
treatment-related deaths. Median LVEF at baseline was
62% and 59% at the end of trastuzumab (recorded for
43 patients). Only a patient discontinued trastuzumab in
combination due to grade 2 asymptomatic decrease in LVEF
to 40% (baseline 60%). Six patients experienced a reversible
asymptomatic decrease in LVEF between 10% and 15%
reversible with a short treatment arrest. Two patients developed
reversible tachycardia. A transient increase in transaminases
was observed in two patients.
Only a patient discontinued treatment due to grade 3
symptomatic increase in bilirubin.
Fever was recorded in four patients, two after the first
infusion. Four patient lamented fatigue and a transient rash
developed in a patient. The different observed side-effects
related to trastuzumab administration are summarized in
Table 3.
Typical toxic effects of the different chemotherapy agents
used in the associations were not increased by the concomitant
use of trastuzumab.
After a median time of 12 months of trastuzumab therapy
(range 4–22), 11 patients (16%) developed brain metastates
(BM).
discussion
The clinical introduction of trastuzumab for MBC
overexpressing the HER2 protein has changed the clinical
outcome of these patients. Trastuzumab can be combined with
Table 2. Tumor response
No. of
patients (%)
First-line response (70 pts)
ORR 29 (41)
CR 6 (8)
PR 23 (33)
SD 33 (47)
PD 8 (12)
Second-line response (26 pts)
ORR 6 (23)
CR 0
PR 6 (23)
SD 16 (62)
PD 4 (15)
Beyond second-line response (9 pts)
ORR 2 (22)
CR 1 (11)
PR 1 (11)
SD 7 (78)
PD 0
CR, complete response; PR, partial response; SD, stable disease; PD,
progressive disease; ORR, overall response rate.
Table 3. Side-effects related to trastuzumab administration
Types NCI-CTC grade
1 2 3
Cardiac left ventricular
function
6 1 –
Cardiac arrhythmia 2 – –
Fever 4 – –
Rash 1 – –
Fatigue 4 – –
Increase of bilirubin – – 1
Increase of liver
transaminases2
– –
2NCI-CTC, National Cancer Institute Common Toxicity Criteria.
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a wide range of chemotherapy drugs, adding little the toxicity
profile of chemotherapy. Discontinuation after disease
progression is still standard of care, although different trials
report a benefit from the treatment beyond disease progression,
changing chemotherapy regimen [21,22,23].
The potential benefit in responding patients with MBC to
continue trastuzumab with a new chemotherapy drug in
monotherapy is a topic of great interest.
We have reported our long-term clinical experience on
safety and efficacy profile of trastuzumab. Although with
a limited number of patients and in a retrospective report we
have no observed significant difference in (TTP) between the
different lines of treatment, that should be related to the
potential benefit from continued combination treatment,
supported also by the clinical benefit obtained. Moreover,
we have reported a CR in third line in a patient, who had
obtained a SD in first line and a PR in the second. This
clinical outcome is unclear, but certainly is related to the
complex interactions between HER2 pathway and neoplastic
cells.
Controversial is also the higher incidence of BM during
trastuzumab treatment [24, 25] that should reflect the
improved peripheral tumor control and patient survival and
the relative lack of activity of trastuzumab on central nervous
system. The incidence of BM in our patients (16%) is in the
range commonly reported for breast cancer patients [25].
Prolonged administration of trastuzumab seems to be a safe
approach, with manageable toxic effects. The available data
indicate that often cardiotoxicity of trastuzumab therapy may
reflect an exacerbation of anthracycline-induced cardiotoxicity
in previous treatments [10], usually not clinical relevant. The
only grade 2 cardiotoxicity reported in our report was observed
in a patient previously treated in metastatic setting with first-
line anthracycline-based chemotherapy.
Twenty-five of our patients were heavily pretreated for
metastatic disease (13 patients have also received adjuvant
chemotherapy), but have shown a good compliance to the
treatment, confirming the good safety profile of trastuzumab.
In summary, the introduction of trastuzumab in our clinical
practice has certainly revolutioned the treatment of breast
cancer with the development of new active therapeutic options.
Even with the large therapeutic benefits of trastuzumab,
avoiding toxic effects remains an important goal and physicians
must be vigilant in managing toxic effects and evaluating
potential benefits and risk. Further research is warranted to
resolve some important controversies on its optimal use.
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